Astellas : FDA Grants Priority Review For SBLA Of Padcev Combination For Bladder Cancer Treatment
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – Astellas Pharma Inc. (ALPMY, ALPMY) and Seagen Inc. (SGEN) said that the U.S. Food and Drug Administration accepted for priority review a supplemental Biologics License Application or sBLA for Padcev (enfortumab vedotin-ejfv) with Keytruda (pembrolizumab) as a combina
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1190222745-b65de6b6c3b948d2a22db5d28c5b1fb8.jpg "Is My Credit Score Good Enough for a Mortgage?")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1390654298-5468501d88fb4e7faca533096301f91c-10635296cf604385879a8a0cdb404622.jpg "Best Strategies for Your Roth 401(k)")
:max_bytes(150000):strip_icc():format(jpeg)/socialsecurity-whentoapply-794e7d2e1615450a9c7530288e2f5dad.jpg "Unlocking Benefits: The Best Time to Apply for Social Security")
:max_bytes(150000):strip_icc():format(jpeg)/creditscorecheck-c254d4f39aae46919b846f0f391011c6.jpg "Watch Out for These Top Internet Scams")